Modulation of bio-electrical rhythms via a novel engineering approach
    1.
    发明授权
    Modulation of bio-electrical rhythms via a novel engineering approach 失效
    通过新颖的工程方法调制生物电节律

    公开(公告)号:US08658609B2

    公开(公告)日:2014-02-25

    申请号:US11701985

    申请日:2007-02-02

    IPC分类号: A61K48/00

    摘要: The present invention relates to novel compositions and methods to induce, and/or modulate bio-electrical rhythms (e.g. in cardiac, neuronal and pancreatic cells) by fine-tuning the activity of HCN-encoded pacemaker channels via a novel protein- and genetic-engineering approach to augment or attenuate the associated physiological responses (e.g. heart beat, neuronal firing, insulin secretion, etc) for achieving various therapeutic purposes (e.g. sick sinus syndrome, epilepsy, neuropathic pain, diabetes, etc).

    摘要翻译: 本发明涉及通过经由新的蛋白质和遗传学方法微调HCN编码的起搏器通道的活性来诱导和/或调节生物电节律(例如在心脏,神经元和胰腺细胞中)的新组合物和方法, 用于实现各种治疗目的(例如,病态窦综合征,癫痫,神经性疼痛,糖尿病等)的相关生理反应(例如心跳,神经元激发,胰岛素分泌等)的工程方法。

    Modulation of bio-electrical rhythms via a novel engineering approach
    2.
    发明申请
    Modulation of bio-electrical rhythms via a novel engineering approach 失效
    通过新颖的工程方法调制生物电节律

    公开(公告)号:US20090291068A1

    公开(公告)日:2009-11-26

    申请号:US11701985

    申请日:2007-02-02

    IPC分类号: A61K35/12 C12N5/06 A61K48/00

    摘要: The present invention relates to novel compositions and methods to induce, and/or modulate bio-electrical rhythms (e.g. in cardiac, neuronal and pancreatic cells) by fine-tuning the activity of HCN-encoded pacemaker channels via a novel protein- and genetic-engineering approach to augment or attenuate the associated physiological responses (e.g. heart beat, neuronal firing, insulin secretion, etc) for achieving various therapeutic purposes (e.g. sick sinus syndrome, epilepsy, neuropathic pain, diabetes, etc).

    摘要翻译: 本发明涉及通过经由新的蛋白质和遗传学方法微调HCN编码的起搏器通道的活性来诱导和/或调节生物电节律(例如在心脏,神经元和胰腺细胞中)的新组合物和方法, 用于实现各种治疗目的(例如,病态窦综合征,癫痫,神经性疼痛,糖尿病等)的相关生理反应(例如心跳,神经元激发,胰岛素分泌等)的工程方法。

    Novel Genetic Approaches to Reduce or Inhibit Tumorgenicity of Human Embryonic Stem Cells and Derivatives Following Transplantation
    3.
    发明申请
    Novel Genetic Approaches to Reduce or Inhibit Tumorgenicity of Human Embryonic Stem Cells and Derivatives Following Transplantation 审中-公开
    减少或抑制移植后人类胚胎干细胞和衍生物的肿瘤侵袭的新型遗传方法

    公开(公告)号:US20110008888A1

    公开(公告)日:2011-01-13

    申请号:US11884987

    申请日:2006-02-23

    IPC分类号: C12N5/079 C12N5/071

    摘要: Self-renewable embryonic stem cells (ESCs), derived from the inner cell mass of blastocysts, can propagate indefinitely in culture while maintaining their normal karyotypes and pluripotency to differentiate into all cell types. Therefore, ESCs may provide an unlimited supply of even specialized cells such as brain and heart cells for transplantation and cell-based therapies that are otherwise limited by donor availability. However, this promising application is hampered by concerns that ESCs or their multipotent derivatives also possess the potential to form malignant tumors after transplantation in vivo. The present invention provides for a novel genetic method to arrest undesirable cell division (of ESCs and other unwanted lineages) as a means to inhibit or eliminate their tumorgenic potential after transplantation.

    摘要翻译: 源自囊胚内细胞团的自体再生胚胎干细胞(ESCs)可以在培养物中无限期繁殖,同时保持其正常核型和多能性分化成所有细胞类型。 因此,ESCs可能提供无限量的甚至特殊的细胞,例如用于移植的脑和心脏细胞,以及由供体可用性限制的基于细胞的疗法。 然而,这种有希望的应用受到了ESCs或其多能衍生物也具有在体内移植后形成恶性肿瘤的潜力的阻碍。 本发明提供了一种用于阻止不期望的细胞分裂(ESCs和其他不需要的谱系)的遗传方法作为在移植后抑制或消除其肿瘤发生潜力的手段。